$Intensity Therapeutics(INTS.US)$Intensity Therapeutics Announced A Business Update Reflecting Progress In Its Phase 3 Sarcoma Clinical Program; FDA Provided "Study May Proceed Letter" For Phase 3 Within 30 Day Period Following IND Submission Benzinga· 3 mins ago
$Tharimmune(THAR.US)$on MEGA WATCH 📢 🎅 🔥 biotech company focused on interventions for inflammatory and oncologic diseases 🔥 Strong technical setup: 4-hour chart demonstrating bullish descending wedge 🔥 Strong pipeline with recently published positive Phase 1 data for TH104, its lead candidate for chronic pruritus in PBC 🔥 Market cap $1m, highly undervalued, should easily be a minimum $6m market cap 🔥Oversold, RSI 25 🔥 Recently closed offering (priced at $1.00/sh),...
+4
4
1
報告
Double_Bottom :
looks like public offering of 10 millions shares diluted the stock price. despite the current good news stock price remain downward trend.
Big Bully 81スレ主 :
I'm long as well, averaged down and bought the dip. but ya man that drop was brutal, hopefully up from here, 3700 at 6.75 average, let's go!! GL
Talamo's experience is expected to help the company transition as they aim to treat solid tumors with INT230-6. His joining is crucial as the lead drug, INT230-6, is set to enter a Phase 3 trial.
$Intensity Therapeutics(INTS.US)$ potentially groundbreaking anti-cancer therapy without the conventional oncologic therapeutic side effects. As a health care provider, I will tell you: this is huge!
3
1
報告
Jaguar8 :
Indeed. An RCT trial result is compelling.
Intensity Therapeuticsに関するコメント
Ph2 readouts in Q1 2024...
$リープ・セラピューティクス(LPTX.US)$ Phase 2
$ヴェラ・セラピューティクス(VERA.US)$ Phase 2b
$4Dモレキュラー・セラピューティクス(FDMT.US)$ Phase 2
$アドベラム・バイオテクノロジーズ(ADVM.US)$ Phase 2
$デナリ・セラピューティクス(DNLI.US)$ Phase 2
$アケロ・セラピューティクス(AKRO.US)$ Phase 2b
$スプルース・バイオサイエンシズ(SPRB.US)$ Phase 2
$ゼンコー(XNCR.US)$ Phase 2
$アルナイラム・ファーマシューティカルズ(ALNY.US)$ Phase 2
$ハーモニー・バイオサイエンシーズ(HRMY.US)$ Phase 2
$アネクソン(ANNX.US)$ Phase 2a
$ロイバント・サイエンシズ(ROIV.US)$...
Update
Benzinga· 3 mins ago
THAR on MEGA WATCH 📢 🎅 🎄
🔥 biotech company focused on interventions for inflammatory and oncologic diseases
🔥 Strong technical setup: 4-hour chart demonstrating bullish descending wedge
🔥 Strong pipeline with recently published positive Phase 1 data for TH104, its lead candidate for chronic pruritus in PBC
🔥 Market cap $1m, highly undervalued, should easily be a minimum $6m market cap
🔥Oversold, RSI 25
🔥 Recently closed offering (priced at $1.00/sh),...
Yooo
hooo
Watchlist for Monday, December 11 🎅 🎄 📢 :
Crossing fingers for a good holiday rally 🎅 ☃️
$Intensity Therapeutics(INTS.US)$
$African Agriculture(AAGR.US)$
$シングン(CYN.US)$
$PaxMedica Inc(PXMD.US)$
$U Power(UCAR.US)$
$ウィサ・テクノロジーズ(WISA.US)$
$SPDR S&P 500 ETF(SPY.US)$
...
Groundbreaking Intervention
As a health care provider, I will tell you: this is huge!
まだコメントはありません